Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006400 · ClinicalTrials.gov registry record · Phase 3
Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia
A Phase 3 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 3
- Development phase
- 193
- Enrollment target
NCT00006400 is a Phase 3 study that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 193 participants.
The verdict
NCT00006400, a Phase 3 study, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 193 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if hydroxyurea therapy is effective in the prevention of chronic end organ damage in pediatric patients with sickle cell anemia.
Interventions
- DRUG Placebo
- DRUG Hydroxyurea
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2000-08 |
| Est. Completion | 2009-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006400
The ClinicalTrials.gov registry entry for NCT00006400 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 193 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00006400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006400 about?
NCT00006400 is a clinical study titled "Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia". The purpose of this study is to determine if hydroxyurea therapy is effective in the prevention of chronic end organ damage in pediatric patients with sickle cell anemia.
What is the current status of trial NCT00006400?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 193 participants. The study started on 2000-08. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00006400?
The interventions under investigation include: Placebo (DRUG), Hydroxyurea (DRUG).
Who is sponsoring clinical trial NCT00006400?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.